BioNano Genomics Statistics
BioNano Genomics (0A4K) Stock Statistics & Valuation Metrics
Total Valuation
BioNano Genomics has a market cap or net worth of $13.31M. The enterprise value is $16.58M.
- Market Cap
- $13.31M
- Enterprise Value
- $16.58M
Share Statistics
BioNano Genomics has 13,979,584 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,979,584
- Owned by Insiders
- 0.96%
- Owned by Institutions
- 11.53%
Financial Efficiency
BioNano Genomics’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -64.63%.
- Return on Equity (ROE)
- -0.59
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -64.63%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 296.96K
- Profits Per Employee
- -274.95K
- Employee Count
- 96
- Asset Turnover
- 0.39
- Inventory Turnover
- 4.08
Valuation Ratios
The current PE Ratio of BioNano Genomics is -0.36. BioNano Genomics’s PEG ratio is -0.00.
- PE Ratio
- -0.36
- PS Ratio
- 0.43
- PB Ratio
- 0.41
- Price to FCF
- -0.70
- Price to Operating Cash Flow
- -0.60
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, BioNano Genomics had revenue of 28.51M and earned -26.39M in profits. Earnings per share was -4.85.
- Revenue
- 28.51M
- Gross Profit
- 6.26M
- Operating Income
- -33.34M
- Pretax Income
- -26.33M
- Net Income
- -26.39M
- EBITDA
- -16.30M
- Earnings Per Share (EPS)
- -4.85
Cash Flow
In the last 12 months, operating cash flow was -19.09M and capital expenditures 0, giving a free cash flow of -19.09M billion.
- Operating Cash Flow
- -19.09M
- Free Cash Flow
- -19.09M
- Free Cash Flow per Share
- -1.59
Dividends & Yields
BioNano Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -142.54%
- Earnings Yield
- -262.19%
Stock Price Statistics
- Beta
- 0.66
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 5.25
- 200-Day Moving Average
- 5.25
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
BioNano Genomics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
BioNano Genomics as a current ratio of 1.98, with Debt / Equity ratio of 15.57%
- Current Ratio
- 1.98
- Quick Ratio
- 1.74
- Debt to Market Cap
- 0.72
- Net Debt to EBITDA
- -0.24
- Interest Coverage Ratio
- -111.88
Taxes
In the past 12 months, BioNano Genomics has paid 67.00K in taxes.
- Income Tax
- 67.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
BioNano Genomics EV to EBITDA ratio is -0.68, with an EV/FCF ratio of -0.82.
- EV to Sales
- 0.50
- EV to EBITDA
- -0.68
- EV to Free Cash Flow
- -0.82
- EV to Operating Cash Flow
- -0.82
Balance Sheet
BioNano Genomics has $4.36M in cash and marketable securities with $6.54M in debt, giving a net cash position of -$2.19M billion.
- Cash & Marketable Securities
- $4.36M
- Total Debt
- $6.54M
- Net Cash
- -$2.19M
- Net Cash Per Share
- -$0.16
- Tangible Book Value Per Share
- $2.33
Margins
Gross margin is 47.98%, with operating margin of -97.11%, and net profit margin of -96.87%.
- Gross Margin
- 47.98%
- Operating Margin
- -97.11%
- Pretax Margin
- -96.68%
- Net Profit Margin
- -96.87%
- EBITDA Margin
- -73.34%
- EBIT Margin
- -96.00%
Analyst Forecast
The average price target for BioNano Genomics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.00
- Price Target Upside
- 23.87% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 8.23%
- EPS Growth Forecast
- 82.76%

